{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T16:41:49Z","timestamp":1750524109606},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Private Universit\u00e4t Witten\/Herdecke gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Wir berichten \u00fcber den Fall eines atypischen Therapieverlaufs bei amyopathischer MDA5-Antik\u00f6rper-positiver Dermatomyositis mit Lungenbeteiligung. Aufgrund der schlechten Prognose erfolgte initial neben der Gabe von Prednisolon die fr\u00fchzeitige Therapie mit Cyclophosphamid, gefolgt von Rituximab. Aufgrund des Therapieversagens erfolgte die Umstellung der Basistherapie auf Mycophenolat-Mofetil. Hierunter zeigte sich ein \u00fcberraschend rascher positiver Verlauf bez\u00fcglich der Lungenver\u00e4nderungen, der Hautver\u00e4nderungen und der allgemeinen Krankheitsaktivit\u00e4t.<\/jats:p>","DOI":"10.1007\/s00108-023-01517-x","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T12:02:08Z","timestamp":1685448128000},"page":"805-809","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapiealternativen bei amyopathischer MDA5-positiver Dermatomyositis","Treatment alternatives for amyopathic MDA5-positive dermatomyositis"],"prefix":"10.1007","volume":"64","author":[{"given":"Falk","family":"Schumacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Wollsching-Strobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doreen","family":"Kroppen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah Bettina","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Strunk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfram","family":"Windisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"issue":"1","key":"1517_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg\u00a0IE, Fujimoto\u00a0M, Vencovsky\u00a0J et\u00a0al (2021) Idiopathic inflammatory myopathies. Nat Rev Dis Primers 7(1):86. https:\/\/doi.org\/10.1038\/s41572-021-00321-x","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"1517_CR2","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s10067-007-0562-9","volume":"26","author":"S Ye","year":"2007","unstructured":"Ye\u00a0S, Chen\u00a0X, Lu\u00a0X et\u00a0al (2007) Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a\u00a0retrospective cohort study. Clin Rheumatol 26(10):1647\u20131654. https:\/\/doi.org\/10.1007\/s10067-007-0562-9","journal-title":"Clin Rheumatol"},{"issue":"3","key":"1517_CR3","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3109\/14397595.2015.1014140","volume":"27","author":"Y Koichi","year":"2017","unstructured":"Koichi\u00a0Y, Aya\u00a0Y, Megumi\u00a0U et al (2017) A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a\u00a0patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol 27(3):536\u2013540. https:\/\/doi.org\/10.3109\/14397595.2015.1014140","journal-title":"Mod Rheumatol"},{"issue":"7","key":"1517_CR4","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","volume":"37","author":"H So","year":"2018","unstructured":"So\u00a0H, Wong\u00a0VTL, Lao\u00a0VWN, Pang\u00a0HT, Yip\u00a0RML (2018) Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. Clin Rheumatol 37(7):1983\u20131989. https:\/\/doi.org\/10.1007\/s10067-018-4122-2","journal-title":"Clin Rheumatol"},{"key":"1517_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-222060","author":"K Parperis","year":"2018","unstructured":"Parperis\u00a0K, Kiyani\u00a0A (2018) Clinically amyopathic dermatomyositis associated with anti-MDA5 antibody. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2017-222060","journal-title":"BMJ Case Rep"},{"key":"1517_CR6","doi-asserted-by":"publisher","first-page":"151959","DOI":"10.1016\/j.semarthrit.2022.151959","volume":"53","author":"M McPherson","year":"2022","unstructured":"McPherson\u00a0M, Economidou\u00a0S, Liampas\u00a0A, Zis\u00a0P, Parperis\u00a0K (2022) Management of MDA\u20115 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review. Semin Arthritis Rheum 53:151959. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151959","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"1517_CR7","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1111\/1756-185X.13136","volume":"20","author":"J Hisanaga","year":"2017","unstructured":"Hisanaga\u00a0J, Kotani\u00a0T, Fujiki\u00a0Y, Yoshida\u00a0S, Takeuchi\u00a0T, Makino\u00a0S (2017) Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis. Int J Rheum Dis 20(12):2182\u20132185. https:\/\/doi.org\/10.1111\/1756-185X.13136","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"1517_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z Chen","year":"2019","unstructured":"Chen\u00a0Z, Wang\u00a0X, Ye\u00a0S (2019) Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N\u00a0Engl J Med 381(3):291\u2013293. https:\/\/doi.org\/10.1056\/NEJMc1900045","journal-title":"N Engl J Med"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01517-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-023-01517-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01517-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T07:02:04Z","timestamp":1690182124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-023-01517-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":8,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1517"],"URL":"https:\/\/doi.org\/10.1007\/s00108-023-01517-x","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"28 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Schumacher, M.\u00a0Wollsching-Strobel, D.\u00a0Kroppen, S.B.\u00a0Schwarz, J.\u00a0Strunk, W.\u00a0Windisch und M.\u00a0Berger geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}